98555-00-1

Basic information

• Product Name: 7-AMINO-2(1H)-QUINOXALINONE
• Synonyms: 7-AMINO-2(1H)-QUINOXALINONE;TIMTEC-BB SBB014164;7-AMinoquinoxalin-2(1H)-one;7-aminoquinoxalin-2-ol
• CAS NO: 98555-00-1
• Molecular Formula: C8H7N3O
• Molecular Weight: 161.16
• Mol File: 98555-00-1.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.49 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 7-AMINO-2(1H)-QUINOXALINONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-AMINO-2(1H)-QUINOXALINONE(98555-00-1)
• EPA Substance Registry System: 7-AMINO-2(1H)-QUINOXALINONE(98555-00-1)

Safety Data

• Hazardous Substances Data: 98555-00-1(Hazardous Substances Data)

Usage

General Description

7-Amino-2(1H)-quinoxalinone, also known as 7-AQ, is a heterocyclic chemical compound with a quinoxalinone core structure. It is a yellow crystalline solid that is used in various chemical and pharmaceutical applications. 7-AQ is a versatile building block for the synthesis of various organic compounds and is also used as an intermediate in the production of pharmaceuticals, dyes, and agrochemicals. It has been studied for its potential anticancer and antiviral properties, and has shown inhibitory activity against several enzymes and receptors. 7-Amino-2(1H)-quinoxalinone is considered to be a valuable compound in the field of organic chemistry and has potential applications in the development of new drugs and materials.

Upstream product

• 251474-50-7 7-amino-3,4-dihydro-1H-quinoxalin-2-one 
• 89898-96-4 7-nitroquinoxaline-2(1H)-one 
• 1084-76-0 DNP-Gly 
• 95-54-5 1,2-diamino-benzene 
• 55686-94-7 2-Chloro-7-nitroquinoxaline 
• 1196-57-2 quinoxalin-2⁽¹⁾-one 

Downstream Products

• 166402-16-0 6-amino-3-chloroquinoxaline 

Relevant articles and documents

Oxidative Cyclization-Induced Activation of a Phosphoinositide 3-Kinase Inhibitor for Enhanced Selectivity of Cancer Chemotherapeutics

In this work, we designed a prodrug that reacts with cellular oxidative equivalents leading to ether cleavage and cyclization to release an active phosphatidylinositol 3-kinase (PI3K) inhibitor. We show that the compound reduces affinity for PI3KA relative to the PI3K inhibitor, is slow to intercellularly oxidize, and is resistant to liver microsomes. We observed modest activity in untreated acute myeloid leukemia cells and 14-fold selectivity relative to non-cancerous cells. The cellular activity of the compound can be modulated by the addition of antioxidants or oxidants, indicating the compound activity is sensitive to cellular reactive oxygen species (ROS) state. Co-treatment with cytosine arabinoside or doxorubicin was used to activate the compound inside cells. We observed strong synergistic activity specifically in acute myeloid leukemia (AML) cancer cells with an increase in selective anticancer activity of up to 90-fold. Thus, these new self-cyclizing compounds can be used to increase the selectivity of anticancer agents.